US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
1. FDA expands Moderna's RSV vaccine usage to high-risk adults aged 18-59 years.
FAQ
Why Bullish?
The FDA's decision broadens MRNA's market potential, mirroring past successes of similar approvals that propelled stock prices upward.
How important is it?
The expansion of the vaccine's use indicates potential revenue growth, generating positive investor sentiment.
Why Short Term?
Immediate market response likely follows FDA announcements, as demonstrated with their COVID-19 vaccine approvals.